The revamp of French drugmaker Ipsen has continued with a takeover agreement for US counterpart Epizyme and its cancer therapy Tazverik, in a deal valued at a little under $250 million. Ipsen is ...

"FOP is a progressive and debilitating condition which has such a profound impact on patients, and their families," said Dr Howard Mayer, Ipsen's head of R&D. "Until today, there was no approved ...

Biomunex CEO, founder and president Dr Pierre-Emmanuel Gerard stated: “This agreement with such an innovative oncology company as Ipsen is proof of the relevance of the MAIT-engager approach of ...